Technical Analysis for XNCR - Xencor, Inc.

Grade Last Price % Change Price Change
grade F 29.94 -6.73% -2.16
XNCR closed down 6.73 percent on Friday, March 22, 2019, on approximately normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical XNCR trend table...

Date Alert Name Type % Chg
Mar 22 Fell Below 20 DMA Bearish 0.00%
Mar 22 Bollinger Band Squeeze Range Contraction 0.00%
Mar 22 Multiple of Ten Bearish Other 0.00%
Mar 21 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -6.73%
Mar 21 Bollinger Band Squeeze Range Contraction -6.73%
Mar 21 Calm After Storm Range Contraction -6.73%
Mar 21 BB Squeeze + Upper Band Touch Range Contraction -6.73%
Mar 21 Inside Day Range Contraction -6.73%
Mar 21 Upper Bollinger Band Touch Strength -6.73%
Mar 20 50 DMA Resistance Bearish -7.36%

Older signals for XNCR ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing engineered monoclonal antibodies to treat severe and life-threatening diseases. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions through XmAb technology platform. The company's engineered antibodies that are in development include XmAb5871, a B-cell inhibitor that is in Phase Ib/IIa clinical trials for the treatment of autoimmune diseases, such as rheumatoid arthritis and lupus; XmAb7195, an IgE inhibitor to treat severe asthma and allergic diseases; and XmAb5574/MOR208, a Cytotoxic B-cell depleting product candidate for the treatment of B-cell cancers. It has a collaboration agreement with Boehringer Ingelheim International GmbH; and development and manufacturing services agreement with Catalent Pharma Solutions LLC. The company was founded in 1997 and is based in Monrovia, California.
Medicine Biotechnology Biopharmaceutical Cancer Medical Specialties Life Sciences Immunology Antibodies Immune System Monoclonal Antibodies Autoimmune Diseases Rheumatoid Arthritis Antibody Glycoproteins Treatment Of Autoimmune Diseases Lupus Boehringer Ingelheim Immunoglobulin E Manufacturing Services Agreement
Is XNCR a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 3 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 48.38
52 Week Low 27.57
Average Volume 240,226
200-Day Moving Average 37.3671
50-Day Moving Average 33.016
20-Day Moving Average 30.3335
10-Day Moving Average 30.133
Average True Range 1.7762
ADX 27.0
+DI 26.283
-DI 23.8763
Chandelier Exit (Long, 3 ATRs ) 29.9614
Chandelier Exit (Short, 3 ATRs ) 33.0786
Upper Bollinger Band 32.6145
Lower Bollinger Band 28.0525
Percent B (%b) 0.41
BandWidth 15.039478
MACD Line -0.7345
MACD Signal Line -1.0687
MACD Histogram 0.3343
Fundamentals Value
Market Cap 1.4 Billion
Num Shares 46.9 Million
EPS -0.87
Price-to-Earnings (P/E) Ratio -34.41
Price-to-Sales 29.06
Price-to-Book 3.08
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 32.84
Resistance 3 (R3) 33.15 32.51 32.35
Resistance 2 (R2) 32.51 31.77 32.35 32.19
Resistance 1 (R1) 31.22 31.31 30.90 30.91 32.03
Pivot Point 30.58 30.58 30.42 30.42 30.58
Support 1 (S1) 29.29 29.84 28.97 28.98 27.85
Support 2 (S2) 28.65 29.38 28.49 27.69
Support 3 (S3) 27.36 28.65 27.53
Support 4 (S4) 27.05